KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Pegylated granulocyte colony-stimulating factor primary prophylaxis versus no prophylaxis in patients with unresectable pancreatic cancer treated with modified-FOLFIRINOX: a randomized, open-label, multicenter, phase 2 trial. PMID 41324016 · EClinicalMedicine · 2025-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China. PMID 41324015 · EClinicalMedicine · 2025-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Preliminary Outcomes of a Culturally Adapted Fear of Recurrence Therapy (FORT) for Turkish Breast Cancer Survivors: A Randomized Controlled Trial. PMID 41318944 · Psychooncology · 2025-Dec The study is an oncology, human, randomized trial reporting original results. However, it is excluded because: 1) The intervention is a non-drug psychological therapy (FORT), not a drug-containing intervention. 2) The primary and secondary outcomes are psychological and quality-of-life measures (FCR, anxiety, depression, etc.), not the required time-to-event efficacy endpoints (OS, PFS, DFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study. PMID 41318310 · Dig Liver Dis · 2025-Dec 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis. PMID 41317156 · Eur J Heart Fail · 2025-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial. PMID 41314741 · Lancet HIV · 2025-Dec 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registry. PMID 41313970 · ESMO Open · 2025-Dec Eligible. This is a final report of a randomized trial in HR-positive early breast cancer with drug-containing chemotherapy arms, reporting 10-year time-to-event efficacy endpoints (iDFS, dDFS, OS). The trial is described as a randomized controlled trial. The registry follow-up provides final long-term results from the original randomized PlanB trial. The phase is inferred as definitive (Phase III) from the context of a randomized trial with standard chemotherapy arms, though not explicitly stated in metadata.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 2 Figure · 6 Panel · risk visible
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX). PMID 41313969 · ESMO Open · 2025-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of Tan Yin Wan in preventing acute exacerbations of COPD: A multicenter, randomized, double-blind, placebo-controlled, phase Ⅳ clinical trial. PMID 41313848 · Phytomedicine · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Randomized Trial of Sentinel Node Biopsy Omission After Neoadjuvant Systemic Therapy in Clinically Node-Negative or Selected Node-Positive Breast Cancer. PMID 41311332 · J Breast Cancer · 2025-Dec The record describes a registered randomized trial protocol for a surgical intervention (omission of sentinel lymph node biopsy) after neoadjuvant systemic therapy. It reports no results. The phase is not explicitly stated as Phase III/IIIb or Phase II/III, and the intervention is not a drug (it is a comparison of surgical procedures). Therefore, it is not an eligible report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Double-Blind Randomized Sham-Controlled Trial of Two Online Cognitive Bias Modification Interventions for Fear of Cancer Recurrence in People With Breast or Ovarian Cancer. PMID 41310810 · Psychooncology · 2025-Dec The study is a randomized oncology trial with original results, but it does not meet eligibility because it lacks a time-to-event efficacy endpoint and uses a non-drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial. PMID 41308679 · Lancet Oncol · 2025-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study. PMID 41308676 · Lancet Oncol · 2025-Dec 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial. PMID 41308674 · Lancet Oncol · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial. PMID 41308673 · Lancet Oncol · 2025-Dec 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Maintained improvement of outcomes related to skin clearance, itch, sleep and quality of life with baricitinib in adults with moderate-to-severe Atopic Dermatitis who were treated for up to 200 weeks in a randomized trial. PMID 41306112 · J Dermatolog Treat · 2025-Dec 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study. PMID 41297162 · ESMO Open · 2025-Dec 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H L S B
旧组与严格 v3 交集 eligibleexplicit_phase3_randomized confirmed 1 Figure · 3 Panel · risk visible
PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort. PMID 41297161 · ESMO Open · 2025-Dec The record describes a retrospective real-world cohort study evaluating the pathological complete response (pCR) rate of a regimen used in a prior Phase III trial. It is not an original report of a randomized Phase III trial, and its primary endpoint (pCR) is not a time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Bayesian Prediction of Event Times Using Mixture Model for Blinded Randomized Controlled Trials. PMID 41290204 · Stat Med · 2025-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Minimally Invasive versus Open Pancreatoduodenectomy for Resectable Neoplasms. PMID 41288428 · NEJM Evid · 2025-Dec 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial. PMID 41288059 · J Dermatolog Treat · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Tumor-Informed ctDNA in Guiding First-Line Immunochemotherapy in Advanced Non-Small Cell Lung Cancers. PMID 41287887 · Adv Sci (Weinh) · 2025-Dec 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 3 Figure · 10 Panel · risk unclear
Can Prostate Cancer Screening Reduce Mortality in Men Aged 75-79 Years? A Protocol for Target-trial Emulation. PMID 41280154 · Eur Urol Open Sci · 2025-Dec 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Evaluating Circulating Tumor DNA Clearance as an Early Intermediate End Point Predicting Clinical Benefit in Metastatic Nonsquamous NSCLC After First-Line Chemoimmunotherapy. PMID 41278397 · JTO Clin Res Rep · 2025-Dec The report is a secondary analysis using data from a Phase III trial (IMpower150) to evaluate ctDNA clearance as a surrogate endpoint. It is not the original, primary, or formal result report of the randomized trial itself, which would present the trial's primary efficacy outcomes. The deterministic review correctly identified the lack of explicit randomization evidence in this secondary analysis, but the more fundamental exclusion is that this is not the trial's result report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Bevacizumab plus chemotherapy versus chemotherapy in untreated advanced non-squamous non-small-cell lung cancer patients with brain metastases (BAP BRAIN): an open-label, randomized, multicenter, phase III study. PMID 41270700 · ESMO Open · 2025-Dec 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 3 Panel · risk unclear
First-line treatment in EGFR-mutated non-small cell lung cancer: brief report of an individual patient data comparison of phase 3 clinical trials. PMID 41270639 · Lung Cancer · 2025-Dec 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H S B
严格 v3 独有 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Matching-adjusted indirect comparison of kidney function in patients with immunoglobulin A nephropathy treated with nefecon or sparsentan. PMID 41263371 · J Comp Eff Res · 2025-Dec 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of lurasidone on anxiety symptoms in patients with schizophrenia: A pooled post hoc analysis of five randomized, placebo-controlled trials. PMID 41262722 · PCN Rep · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study. PMID 41259897 · ESMO Open · 2025-Dec 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 3 Panel · risk unclear
Early onset, maintenance of effect, and day-/night-time findings following fezolinetant treatment for moderate to severe vasomotor symptoms associated with menopause: A pooled phase 3 analysis. PMID 41259888 · Maturitas · 2025-Dec 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Immunogenicity and safety of Biological E's CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A prospective double-blind randomized phase III clinical study. PMID 41245642 · IJID Reg · 2025-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Epstein-Barr virus DNA-guided chemoradiotherapy for patients with low-risk locoregionally advanced nasopharyngeal carcinoma: a secondary 5-year follow-up analysis of an open-label, randomised controlled, phase 2 non-inferiority trial. PMID 41245547 · EClinicalMedicine · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Early stoppage of empirical antibiotic therapy in paediatric acute leukaemia with high-risk febrile neutropenia: a randomized, open-label, phase 3, non-inferiority trial. PMID 41245542 · EClinicalMedicine · 2025-Dec The study is an eligible oncology RCT with drug intervention, but its primary efficacy endpoint is a binary proportion (fever recurrence), not a time-to-event endpoint. Therefore, it does not meet the specific requirement for Kaplan-Meier/HR-based efficacy analysis.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adaptive designs in randomized clinical trials: reanalysis of the HOVON87/NMSG18 multiple myeloma trial. PMID 41245539 · EClinicalMedicine · 2025-Dec This is a methodological reanalysis of an existing Phase III trial, not the original trial report. The abstract does not specify the drug intervention used in the HOVON87/NMSG18 trial, only referencing it as a 'novel drug' trial. The primary focus is on evaluating adaptive trial designs, not reporting the original efficacy results of a specific drug regimen.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: a multicentre, observer-blind, randomised, phase 3 study. PMID 41240950 · Lancet Glob Health · 2025-Dec 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Frequent productive cough in COPD relates to exacerbation risk and treatment benefit from budesonide/glycopyrrolate/formoterol fumarate: a post hoc analysis of KRONOS. PMID 41237914 · Respir Med · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of combining bevacizumab and fractionated stereotactic radiotherapy for extensive brain metastases in patients with non-small cell lung cancer: a prospective phase II study (GASTO-1053). PMID 41235462 · Cancer Commun (Lond) · 2025-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of iclepertin for cognitive impairment associated with schizophrenia (CONNEX programme): results from three phase 3 randomised controlled trials. PMID 41233083 · Lancet Psychiatry · 2025-Dec 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort study. PMID 41232542 · Lancet Oncol · 2025-Dec The record is excluded because it is not a randomized trial, does not involve a drug intervention, and lacks a primary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of gum chewing on the return of bowel sounds, time to first flatus, and defecation after colorectal cancer surgery: A prospective, randomized controlled trial. PMID 41232231 · Eur J Oncol Nurs · 2025-Dec Study is a randomized trial in human colorectal cancer patients, but the intervention is non-drug (gum chewing) and the primary endpoints are postoperative recovery of bowel function, not a standard oncology time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line BRAF V600E-mutant metastatic colorectal cancer. PMID 41230651 · Future Oncol · 2025-Dec Phase III drug trial with time-to-event endpoints, but the provided metadata does not explicitly establish randomization, which is a required criterion for eligibility.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
The Effectiveness of Plecanatide for Treating Constipation and Bloating in Patients Aged 18 to 40 Years With Irritable Bowel Syndrome: Utilization of a New Composite Trisymptom Endpoint. PMID 41214272 · J Gastroenterol Hepatol · 2025-Dec 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of Tegafur-Uracil Maintenance Therapy in Non-Metastatic Head and Neck Squamous Cell Carcinoma: A Meta-Analysis With Trial Sequential Analysis. PMID 41208841 · World J Oncol · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone-releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced Prostate Cancer: The EORTC GUCG-1414 Phase 3 Randomized Trial. PMID 41206286 · Eur Urol Oncol · 2025-Dec While this is a Phase III randomized oncology trial with a time-to-event endpoint (PFS) mentioned, the primary analysis and conclusion focus on a non-drug-related PSA nadir response. The study was closed early, and the drug intervention (degarelix vs. agonist) did not meet the modified primary endpoint. The report does not present a formal efficacy result for a standard time-to-event endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier curves or hazard ratios as required.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
ESR1, PGR, ERBB2, and MKi67 mRNA expression in diagnostic core biopsies from breast cancer patients of the ABCSG Trial 34. PMID 41197528 · Breast · 2025-Dec The record describes a secondary analysis of biomarker concordance and prognostic value within a randomized trial (ABCSG Trial 34), but does not specify a drug-containing intervention or its efficacy. The primary objective is diagnostic assay validation, not a drug treatment comparison.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Systematic review and network meta-analysis: evaluation of systemic therapies for platinum refractory or resistant small cell lung cancer. PMID 41197381 · Lung Cancer · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial. PMID 41194599 · Hum Vaccin Immunother · 2025-Dec 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Clinical characteristics and outcomes in participants with screen-detected clinical stage I lung cancer in the Yorkshire lung screening trial: A comparison of surgery versus stereotactic ablative radiotherapy. PMID 41192094 · Lung Cancer · 2025-Dec The record is an analysis of outcomes from a screening trial cohort comparing surgery vs. SABR for stage I lung cancer. It is oncological, human, randomized (within the screening trial context), reports time-to-event endpoints (OS, CSS), and is an original result. However, it is excluded because it does not involve a drug-containing intervention (surgery and SABR are non-drug modalities) and does not represent a Phase III/IIIb or Phase II/III randomized trial of a drug.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effectiveness of immune checkpoint inhibitor therapy in thyroid cancer: A systematic review. PMID 41192027 · Cancer Treat Rev · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites. PMID 41191932 · NEJM Evid · 2025-Dec 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -